GlassScriptPhysician profile
Kelly M Eckes
NPI 1932620002
$6,757.00
in general payments reported to CMS, 2019-2025
24 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $742 · 2022: $1,300 · 2023: $1,680 · 2024: $1,299 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,665 · Education: $50.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,665.42 |
| Education | $50.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,047.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,005.73 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $1,004.65 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $858.67 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $443.94 | 2022-2024 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $442.50 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Alkermes, INC. | $348.50 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Novo Nordisk INC | $346.71 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $328.26 | 2023-2024 | Uzedy, Austedo Xr, Austedo |
| Idorsia Pharmaceuticals US INC | $165.53 | 2022-2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $153.02 | 2022-2024 | Jornay Pm |
| Boston Scientific Corporation | $128.52 | 2023 | |
| Neurocrine Biosciences, INC. | $98.52 | 2022-2025 | Ingrezza |
| Lilly USA, LLC | $85.30 | 2021-2024 | Jardiance, Zepbound |
| Amgen INC. | $62.22 | 2022-2024 | Otezla, Repatha, Prolia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $44.76 | 2021 | |
| Collegium Pharmaceutical, INC. | $43.46 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $33.71 | 2023-2025 | Qelbree, Qelbree |
| Exact Sciences Corporation | $31.41 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $23.62 | 2021-2022 | |
| Corium, LLC | $18.83 | 2023 | Azstarys |
| Cognoa, INC. | $16.53 | 2023 | Canvas Dx |
| Biogen, INC. | $12.90 | 2021 | |
| Pfizer INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Eckes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.